Shirin Abbasinejad Enger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shirin Abbasinejad Enger has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Luc Beaulieu
Physique, génie physique et optique, Universite Laval, 2375 rue de la Terrasse, 1401 18e rue, Quebec, G1J 1Z4, CANADA
3 shared publications - Mirta Dumančić
Medical Physics Unit, Department of Oncology, Faculty of Medicine McGill University Montréal Québec Canada
3 shared publications - Farhood Farahnak
McGill University Centre for Translational Research in Cancer and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada
2 shared publications - Francisco Berumen
CHU de Québec—Université Laval et Centre de recherche du CHU de Québec
2 shared publications - Jonathan Kalinowski
Medical Physics Unit Department of Oncology Faculty of Medicine McGill University Montréal Quebec Canada
2 shared publications - Joseph M. DeCunha
Department of Physics, Medical Physics Unit, McGill University, Montreal, Quebec, Canada
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Elsevier in SSRN Electronic Journal
MC-ADD: A Geant4 code-generation and analysis workflow for radiation detector prototyping
Monte Carlo simulations are widely used in radiation-detector development and characterization, but developing application-specific Geant4 simulations can require substantial knowledge of its C++ architecture and considerable implementation effort. We developed Monte Carlo Accessible Detector Development (MC-ADD), an open and extensible framework integrating graphical source and detector definition, automatic generation of editable Geant4 source files and macros, radiation transport, mesh-based geometries, and quantitative post-processing. The generated Geant4 application remains directly accessible for application-specific modifications. MC-ADD provides analysis of energy-deposition spectra, three-dimensional hit distributions, detection efficiencies, and voxelized absorbed-dose distributions. The framework was evaluated by comparing ideal and Gaussian-broadened simulated ¹³⁷Cs spectra with experimental measurements. Charged-particle transport was verified by comparing extrapolated α-particle ranges in air and water for ²⁴¹Am, ²²⁴Ra, and monoenergetic α-particle beams with reference databases. Mesh-based modeling was demonstrated using a spiral BCF-12 scintillating-fiber detector irradiated with ¹⁸F. The broadened ¹³⁷Cs spectrum reproduced the main measured spectral features, with a full-energy-peak efficiency of 15.794% ± 0.004%. Extrapolated α-particle ranges differed from reference values by less than 1% in both media, while simulated radionuclide spectra reproduced the principal α-emission energies. The spiral-fiber simulation produced a Compton-dominated deposited-energy spectrum for 511-keV photons and an absolute detection efficiency of 0.4198% ± 0.0007%. These results verify MC-ADD for selected photon and charged-particle transport configurations and demonstrate its use for mesh-based detector modeling. Optical transport, photodetector response, and electronics are not currently included.
- 21 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMC-ADD: A Geant4 code-generation and analysis workflow for radiation detector prototyping
Monte Carlo simulations are widely used in radiation-detector development and characterization, but developing application-specific Geant4 simulations can require substantial knowledge of its C++ architecture and considerable implementation effort. We developed Monte Carlo Accessible Detector Development (MC-ADD), an open and extensible framework integrating graphical source and detector definition, automatic generation of editable Geant4 source files and macros, radiation transport, mesh-based geometries, and quantitative post-processing. The generated Geant4 application remains directly accessible for application-specific modifications. MC-ADD provides analysis of energy-deposition spectra, three-dimensional hit distributions, detection efficiencies, and voxelized absorbed-dose distributions. The framework was evaluated by comparing ideal and Gaussian-broadened simulated ¹³⁷Cs spectra with experimental measurements. Charged-particle transport was verified by comparing extrapolated α-particle ranges in air and water for ²⁴¹Am, ²²⁴Ra, and monoenergetic α-particle beams with reference databases. Mesh-based modeling was demonstrated using a spiral BCF-12 scintillating-fiber detector irradiated with ¹⁸F. The broadened ¹³⁷Cs spectrum reproduced the main measured spectral features, with a full-energy-peak efficiency of 15.794% ± 0.004%. Extrapolated α-particle ranges differed from reference values by less than 1% in both media, while simulated radionuclide spectra reproduced the principal α-emission energies. The spiral-fiber simulation produced a Compton-dominated deposited-energy spectrum for 511-keV photons and an absolute detection efficiency of 0.4198% ± 0.0007%. These results verify MC-ADD for selected photon and charged-particle transport configurations and demonstrate its use for mesh-based detector modeling. Optical transport, photodetector response, and electronics are not currently included.
- Open Access
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emerging cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Open AccessWorldwide Innovative Network Consortium: Building a Common Global Cancer Database
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emerging cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence–driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
- Open Access
- 16 June 2026
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 249
Implementation of temperature–pH coupling in the Geant4-DNA chemistry module for water radiolysis simulations
- 16 June 2026
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 249
Open AccessImplementation of temperature–pH coupling in the Geant4-DNA chemistry module for water radiolysis simulations
- Open Access
- 16 June 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (12) , 12NT02
RapidBrachyMCTPS 3.0: recent updates and validation of RapidBrachyMCTPS, a Monte Carlo-based brachytherapy treatment planning system
Objective. RapidBrachyMCTPS is a Monte Carlo (MC)-based treatment planning system for advanced brachytherapy dosimetry applications. In this work, we present the latest updates in RapidBrachyMCTPS v3.0 and benchmark its dose calculations against published guidelines. Approach. RapidBrachyMCTPS v3.0 introduces a major redevelopment of RapidBrachyMC, its underlying MC dose calculation engine. Simulation times were reduced, greater user control over simulation geometry was enabled, and material definitions were greatly simplified and standardized. Test cases developed by the working group on model-based dose calculation algorithms in brachytherapy (WGDCAB) were used to benchmark dose calculation accuracy and quantify improvements in simulation efficiency relative to v2.0. Main results. For four water phantom-based WGDCAB test cases, mean and root-mean-square dose differences between reference data and RapidBrachyMCTPS v3.0-calculated dose distributions were within the estimated total uncertainty budget of 0.4%. Target structure dose-volume histogram metrics for site-specific WGDCAB test cases, one for gynecological tandem and ring brachytherapy and the other for interstitial breast brachytherapy, showed generally good agreement, within 0.01 Gy or 0.10 percentage points, with the same metrics calculated from reference dose distributions. Observed simulation run times for test cases were on average between 1.63 ± 0.02 and 1.66 ± 0.03 times faster than v2.0 without an applicator model and between 1.45 ± 0.01 and 1.91 ± 0.02 times faster with an applicator model, depending on the applicator modeling scheme used. Significance. RapidBrachyMCTPS v3.0 was well-validated to deliver fast, accurate MC dose calculations alongside robust treatment planning capabilities. It remains freely available to the research community.
- 16 June 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (12) , 12NT02
Open AccessRapidBrachyMCTPS 3.0: recent updates and validation of RapidBrachyMCTPS, a Monte Carlo-based brachytherapy treatment planning system
Objective. RapidBrachyMCTPS is a Monte Carlo (MC)-based treatment planning system for advanced brachytherapy dosimetry applications. In this work, we present the latest updates in RapidBrachyMCTPS v3.0 and benchmark its dose calculations against published guidelines. Approach. RapidBrachyMCTPS v3.0 introduces a major redevelopment of RapidBrachyMC, its underlying MC dose calculation engine. Simulation times were reduced, greater user control over simulation geometry was enabled, and material definitions were greatly simplified and standardized. Test cases developed by the working group on model-based dose calculation algorithms in brachytherapy (WGDCAB) were used to benchmark dose calculation accuracy and quantify improvements in simulation efficiency relative to v2.0. Main results. For four water phantom-based WGDCAB test cases, mean and root-mean-square dose differences between reference data and RapidBrachyMCTPS v3.0-calculated dose distributions were within the estimated total uncertainty budget of 0.4%. Target structure dose-volume histogram metrics for site-specific WGDCAB test cases, one for gynecological tandem and ring brachytherapy and the other for interstitial breast brachytherapy, showed generally good agreement, within 0.01 Gy or 0.10 percentage points, with the same metrics calculated from reference dose distributions. Observed simulation run times for test cases were on average between 1.63 ± 0.02 and 1.66 ± 0.03 times faster than v2.0 without an applicator model and between 1.45 ± 0.01 and 1.91 ± 0.02 times faster with an applicator model, depending on the applicator modeling scheme used. Significance. RapidBrachyMCTPS v3.0 was well-validated to deliver fast, accurate MC dose calculations alongside robust treatment planning capabilities. It remains freely available to the research community.
- Open Access
- 8 May 2026
- Published by Elsevier in Physica Medica
- Vol. 146, 105804
Construction and characterization of an arterial input function measurement system for dynamic PET
- 8 May 2026
- Published by Elsevier in Physica Medica
- Vol. 146, 105804
Open AccessConstruction and characterization of an arterial input function measurement system for dynamic PET
- Open Access
- 1 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Trends in brachytherapy utilization in Canada from 2011 to 2020
- 1 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Open AccessTrends in brachytherapy utilization in Canada from 2011 to 2020
- Open Access
- 15 July 2025
- Published by Wiley in Medical Physics
- Vol. 52 (7) , e17979
Microdosimetry calculations in situ for clinically relevant photon sources and their correlation with the early DNA damage response
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.
- 15 July 2025
- Published by Wiley in Medical Physics
- Vol. 52 (7) , e17979
Open AccessMicrodosimetry calculations in situ for clinically relevant photon sources and their correlation with the early DNA damage response
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.
- Open Access
- 16 June 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (12) , 125009
Assessing radiosensitivity through sublethal damage recovery: a comparison of survival-based and molecular repair kinetics
Objective. This study aimed to determine whether the kinetics of sublethal damage recovery after x-ray irradiation, quantified as the repair half time ( T repair SLD ) derived from split-dose clonogenic survival, correlates with intrinsic radiosensitivity across four human cancer cell lines: HeLa (cervical), PC3 (prostate), and HCT116 and HT29 (colorectal). In addition, the study compared this survival-based indicator with molecular repair kinetics assessed through γH2AX and 53BP1 foci clearance. Approach. By using a phenomenological approach, we assessed sublethal damage recovery kinetics, aiming to determine whether this recovery rate could serve as a biomarker for cancer-specific intrinsic radiosensitivity. Cells were subjected to split-dose 4 Gy irradiation delivered in two fractions of 2 Gy across a 0 to 10 h inter-fraction interval range using a Multi-Rad x-ray irradiator with a peak tube voltage of 225 kV. The clonogenic assay was performed following split-dose irradiation of the experimental groups to assess cell survival. Colonies were fixed, stained, and counted ( ⩾ 50 cells/colony viable threshold) to calculate survival fractions (SFs) from the four independent experimental runs completed for each cell line. Unirradiated control cells were used to calculate plating efficiency. The measured SF as a function of inter-fraction time was fitted with the Lea–Catcheside modified linear-quadratic model with a half-life of sublethal damage repair, T repair SLD , as a free parameter. To compare this approach to molecular DNA repair kinetics, immunofluorescence-based ionizing radiation-induced foci (IRIF) clearance experiments were performed following single 2 Gy irradiation using the same x-ray source. γH2AX and 53BP1 foci were quantified from 0.5 to 24 h post-irradiation, and foci clearance half-lives ( T repair γ H 2 AX and T repair 53 BP 1 ) were determined by single-phase exponential decay fitting. Main results. For all measured cell lines, an increase in SF was observed with increasing inter-fraction time. The estimated T repair SLD varied across cell lines, from 1.07 ± 0.35 h in HT29, to 1.98 ± 0.94 h in HeLa, 2.00 ± 0.30 h in PC3, and 3.58 ± 1.45 h in HCT116, indicating different capacities for sublethal damage repair. A negative correlation was measured between T repair SLD and clonogenic survival at 2 Gy ( SF 2 Gy ) by performing orthogonal distance regression, with a slope of − 350 ± 50 min (p = 0.02). T repair γ H 2 AX and T repair 53 BP 1 ranged from 3 to 11 h, with HT29 showing the fastest foci resolution. However, these molecular repair kinetics times did not significantly correlate with SF 2 Gy (p > 0.05) or follow the same trend as T repair SLD across cell lines. For example, PC3 cells exhibited the slowest foci clearance, whereas HCT116 displayed the slowest T repair SLD , suggesting that IRIF-based measurements do not reliably reflect functional sublethal damage repair. Significance. Clonogenic survival assays capture the integrated biological outcome of radiation exposure, reflecting not only DNA damage recognition and repair but also downstream processes such as checkpoint activation, chromatin context, and long-term proliferative capacity. In contrast, molecular readouts like γH2AX and 53BP1 foci clearance, though rapid and widely used, may not fully account for defects in damage response pathways. The observed discrepancy between foci clearance kinetics and survival-based repair rates in this study highlights the limitations of foci quantification as a surrogate for radiosensitivity. These findings underscore the value of survival-based sublethal damage recovery measurements as functionally rich indicators of intrinsic radiosensitivity, which may inform future biomarker development or predictive modeling frameworks.
- 16 June 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (12) , 125009
Open AccessAssessing radiosensitivity through sublethal damage recovery: a comparison of survival-based and molecular repair kinetics
Objective. This study aimed to determine whether the kinetics of sublethal damage recovery after x-ray irradiation, quantified as the repair half time ( T repair SLD ) derived from split-dose clonogenic survival, correlates with intrinsic radiosensitivity across four human cancer cell lines: HeLa (cervical), PC3 (prostate), and HCT116 and HT29 (colorectal). In addition, the study compared this survival-based indicator with molecular repair kinetics assessed through γH2AX and 53BP1 foci clearance. Approach. By using a phenomenological approach, we assessed sublethal damage recovery kinetics, aiming to determine whether this recovery rate could serve as a biomarker for cancer-specific intrinsic radiosensitivity. Cells were subjected to split-dose 4 Gy irradiation delivered in two fractions of 2 Gy across a 0 to 10 h inter-fraction interval range using a Multi-Rad x-ray irradiator with a peak tube voltage of 225 kV. The clonogenic assay was performed following split-dose irradiation of the experimental groups to assess cell survival. Colonies were fixed, stained, and counted ( ⩾ 50 cells/colony viable threshold) to calculate survival fractions (SFs) from the four independent experimental runs completed for each cell line. Unirradiated control cells were used to calculate plating efficiency. The measured SF as a function of inter-fraction time was fitted with the Lea–Catcheside modified linear-quadratic model with a half-life of sublethal damage repair, T repair SLD , as a free parameter. To compare this approach to molecular DNA repair kinetics, immunofluorescence-based ionizing radiation-induced foci (IRIF) clearance experiments were performed following single 2 Gy irradiation using the same x-ray source. γH2AX and 53BP1 foci were quantified from 0.5 to 24 h post-irradiation, and foci clearance half-lives ( T repair γ H 2 AX and T repair 53 BP 1 ) were determined by single-phase exponential decay fitting. Main results. For all measured cell lines, an increase in SF was observed with increasing inter-fraction time. The estimated T repair SLD varied across cell lines, from 1.07 ± 0.35 h in HT29, to 1.98 ± 0.94 h in HeLa, 2.00 ± 0.30 h in PC3, and 3.58 ± 1.45 h in HCT116, indicating different capacities for sublethal damage repair. A negative correlation was measured between T repair SLD and clonogenic survival at 2 Gy ( SF 2 Gy ) by performing orthogonal distance regression, with a slope of − 350 ± 50 min (p = 0.02). T repair γ H 2 AX and T repair 53 BP 1 ranged from 3 to 11 h, with HT29 showing the fastest foci resolution. However, these molecular repair kinetics times did not significantly correlate with SF 2 Gy (p > 0.05) or follow the same trend as T repair SLD across cell lines. For example, PC3 cells exhibited the slowest foci clearance, whereas HCT116 displayed the slowest T repair SLD , suggesting that IRIF-based measurements do not reliably reflect functional sublethal damage repair. Significance. Clonogenic survival assays capture the integrated biological outcome of radiation exposure, reflecting not only DNA damage recognition and repair but also downstream processes such as checkpoint activation, chromatin context, and long-term proliferative capacity. In contrast, molecular readouts like γH2AX and 53BP1 foci clearance, though rapid and widely used, may not fully account for defects in damage response pathways. The observed discrepancy between foci clearance kinetics and survival-based repair rates in this study highlights the limitations of foci quantification as a surrogate for radiosensitivity. These findings underscore the value of survival-based sublethal damage recovery measurements as functionally rich indicators of intrinsic radiosensitivity, which may inform future biomarker development or predictive modeling frameworks.